In multivariable models (Figure 3B), higher p-tau217/Aβ42 was associated with AD-related factors – diagnosis of MCI (β=0.23, 95%CI=0.02 – 0.44, p=0.033) or ADD (β=0.79, 95%CI=0.46 – 1.12, p<0.001), future progression to MCI/ADD (β=0.33, 95%CI=0.15 – 0.51, p<0.001), older age (β=0.26, 95%CI=0.18 – 0.34, p<0.001), and APOE ε4 carriers (β=0.42, 95%CI=0.27 – 0.57, p<0.001) – as well as lower eGFR (β=−0.23, 95%CI=−0.34 – −0.12, p<0.001) and a history of diabetes (β=0.17, 95%CI=0.00 – 0.33, p=0.049). This evidence concerns the gene APOE and Alzheimer disease.